No Data
No Data
Express News | Barclays Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $55
TD Cowen Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $40 to $88
Intellia Therapeutics | 10-Q: Q3 2024 Earnings Report
Intellia Therapeutics Price Target Lowered to $40 From $41 at JonesResearch
Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript Summary
No Data
No Data
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday